Agios CEO Brian Goff on today's p2 SCD data and how he thinks maitapivat fits into the competitive landscape.

Intellia Therapeutics CEO John Leonard on where he sees gene editing fitting into the practice of medicine.

Jason Park took Empress Therapeutics out of stealth mode today for Flagship Pioneering. He explains Empress’ approach to small molecule drug

Nimbus Therapeutics CEO Jeb Keiper describes his company’s programs and the future of small molecule drug development under the Inflation Re

Ocular Therapeutix CEO Antony Mattessich describes the 12-month data his company has reported for its extended release TKI for wet AMD.

Lou Brenner discusses his company’s raise today and explains how Hopewell is designing LNPs to go beyond the liver.

Cullinan Oncology CEO Nadim Ahmed walks us through the oncology targets the company is focused on and discusses recent ASCO data.

Halozyme CEO Helen Torley describes the technology behind converting infused medicines into subcutaneous injections.

Day One Bio CEO Jeremy Bender describes tovorafenib FIREFLY-1 trial result and Day One’s Plan to seek an accelerated approval for the drug.

Allogene CEO David Chang describes the data his company presented at ASCO on Saturday and makes the case for the durability of the response.

Convergent Therapeutics CEO Phil Kantoff describes the use of targeted radiotherapies against cancer. #ASCO23

Immunogen CEO Mark Enyedy describes Elahere’s MIRASOL trial result and what it means for ovarian cancer and ADCs.

Seagen CEO David Epstein talks about moving antibody-drug conjugates into broader indications at #ASCO23.

Coherus CEO Denny Lanfear talks about trying to lower the cost of medicines through biosimilars and discusses his oncology programs.

Replimune Founder and Head of R&D Robert Coffin describes the oncolytic immunotherapy approach to cancer research.

Arcus Biosciences CEO Terry Rosen describes the ARC-7 TIGIT data update that was presented at #ASCO23.

Xencor CEO Bassil Dahiyat walks us through the idea behind bi-specific antibodies and cytokines in cancer research.

Current BIO Chairman and Nkarta CEO Paul Hastings talks about the policy changes that have been affecting biotech lately, and NK cells.

BridgeBio's Neil Kumar shares experiences that may be good learnings for other drug developers and discusses his company's unique model.

BiotechTV's exclusive interview with Gilead Sciences' Chairman & CEO Dan O'Day on the company's Q1 2023 earnings day.